Cryptococcal meningitis is the leading cause of adult meningitis in sub-Saharan Africa, and contributes up to 20% of AIDS-related mortality in low-income and middle-income countries every year. Antifungal treatment for cryptococcal meningitis relies on three old, off -patent antifungal drugs: amphotericin B deoxycholate, fl ucytosine, and fl uconazole. Widely accepted treatment guidelines recommend amphotericin B and fl ucytosine as fi rst-line induction treatment for cryptococcal meningitis. However, fl ucytosine is unavailable in Africa and most of Asia, and safe amphotericin B administration requires patient hospitalisation and careful laboratory monitoring to identify and treat common sideeff ects. Therefore, fl uconazole monotherapy is widely used in low-income and middle-income countries for induction therapy, but treatment is associated with signifi cantly increased rates of mortality. We review the antifungal drugs used to treat cryptococcal meningitis with respect to clinical eff ectiveness and access issues specifi c to low-income and middle-income countries. Each drug poses unique access challenges: amphotericin B through cost, toxic eff ects, and insuffi ciently coordinated distribution; fl ucytosine through cost and scarcity of registration; and fl uconazole through challenges in maintenance of local stocks-eg, sustainability of donations or insuffi cient generic supplies. We advocate ten steps that need to be taken to improve access to safe and eff ective antifungal therapy for cryptococcal meningitis.
Introduction
The right to health is fi rmly established in international human rights law, and encompasses the right to adequate access to health care and essential medicines. [1] [2] [3] [4] Unfortunately, people in low-income and middle-income countries continue to face large barriers to the access of essential medicines, often with devastating consequences to individuals and public health. Essential medicines are the second largest family expenditure after food for the 90% of the population in the developing world who have to purchase medicines privately. 5 Barriers to access include drug expense, paucity of research and development on diseases predominantly aff ecting low-income and middle-income countries, insuffi cient competition from generic manufacturers, inadequate drug procurement and supply chains, and increasingly constrained global health funding. [6] [7] [8] [9] [10] [11] [12] As a common opportunistic infection in patients with advanced HIV infection, cryptococcal meningitis is the leading cause of meningitis in adults living in sub-Saharan Africa, and contributes to up to 20% of AIDSrelated deaths every year in low-income and middle-income countries. 13 Alth ough increased access to antiretroviral therapy has resulted in a substantial reduction in incidence of cryptococcal meningitis in high-income countries, 14 the infection is likely to remain a major cause of HIV-related mortality in the foreseeable future in lowincome and middle-income countries, where antiretroviral ther apy coverage is insuffi cient and initiated at an advanced stage of HIV. In addition to delays in the diagnosis and treatment of cryptococcal meningitis, poor access to essential antifungal medicines is a major contributor to this unacceptably high mortality. Although fl uconazole monotherapy is associated with increased rates of mortality, inadequate access to alternative treatments means it is widely used in the treatment of cryptococcal meningitis. 15 In this Personal View, we highlight the main obstacles to access of essential antifungal drugs for the treatment of cryptococcal meningitis in patients with HIV in low-income and middle-income countries. We review the three main antifungal drugs for cryptococcal meningitis-amphotericin B, fl ucytosine, and fl uconazole-with re spect to clinical eff ectiveness and access considerations specifi c to low-income and middle-income countries, and suggest steps to improve access to safe and eff ective antifungal treatment for cryptococcal meningitis.
Treatment of HIV-associated cryptococcal meningitis
Both the 2010 Infectious Diseases Society of America (IDSA) and 2011 WHO rapid advice guidelines recommend amphotericin B and fl ucytosine as fi rst-line induction treatment for patients with cryptococcal meningitis, with alternative regimens tailored to individual clinical settings (table 1) . 16, 17 For settings in which fl ucytosine is unavailable, second-line induction treatment consists of amphotericin B and high-dose (800-1200 mg per day) fl uconazole. 16, 17 Where amphotericin B is unavailable or cannot be safely given and moni tored, high-dose fl uconazole and fl ucytosine is recom mended. 16, 17 The initial 2 week induction treatment is followed by consolidation and maintenance phases of treatment with fl uconazole.
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Amphotericin B
Amphotericin B was introduced in the 1950s to treat systemic mycoses. 19 The drug has a broad antifungal range and only few reports of resistance have been documented. 20 Additionally, amphotericin B is used to treat visceral leishmaniasis. 21 Substantial and common side-eff ects of conventional amphotericin B formulations are anaemia, hypokalaemia, hypomag nesaemia, and nephrotoxicity. 22, 23 These eff ects are reversible upon Personal View treatment termination, 23 but are con cerning in settings where availability of blood transfusion and renal replacement treatment is scarce. The need for intravenous administration, monitoring of blood count and renal function, and perception of unmanageable toxic eff ects frequently prevent the use of amphotericin B in poorly resourced and understaff ed hospital settings. Fluid and sodium loading and pre-emptive potassium replacement can reduce the risk of nephrotoxicity, and make administration of amphotericin B in low-income and middle-income countries more feasible. 24 WHO guidelines for the management of cryptococcal meningitis provide clear guidance on how to safely administer amphotericin B deoxycholate. 16 Amphotericin B is the most rapidly acting fungicidal agent against Cryptococcus neoformans. On the basis of evidence from clinical trials, 23,25-31 treatment guidelines for crypto coccal meningitis recommend 2 weeks of amphotericin B-based treatment as fi rst-line treatment, where possible. [16] [17] [18] A strategy of short-course (5-7 days) ampho tericin B was associated with rapid cryptococcal clearance in two African studies, 28, 31 enabling substantial reductions in both cost and toxic eff ects of induction treatment. Although prohibitively expensive for patients in low-income and middleincome countries, liposomal formulations of amphotericin B allow the delivery of high doses of amphotericin B and seem to be at least as eff ective and less nephrotoxic than conventional amphotericin B. 32, 33 Bristol-Myers Squibb (USA) is the main manufacturer of amphotericin B as Fungizone. At least one US Food and Drug Administration (FDA)-approved therapeutic equivalent of amphotericin B is marketed in the USA by X-Gen Pharmaceuticals (USA). 34 The cost of amphotericin B continues to be a barrier to access. 35 Prices range from US$3·51 to $12·20 per 50 mg vial (table 2), which is equivalent to the cost of a daily dose for cryptococcal meningitis treatment for a 50 kg adult, dosed at 1 mg/kg per day. Implementation of amphotericin B is connected with further attendant costs of hospitalisation, intravenous administration, and monitoring of toxic eff ects. Insuffi cient registration of amphotericin B is a challenge in some African countries (table 3) . 37 In 2005, Bristol-Myers Squibb was lobbied for a reduction in the price of amphotericin B in South Africa by the AIDS Law Project on behalf of the Treatment Action Campaign. The Southern African HIV Clinicians Society attained a price reduction from ZAR 146 to ZAR 26 ($18-$3) per 50 mg vial. 35 This reduction made possible the expanded use of amphotericin B and a switch away from initial fl uconazole monotherapy for cryptococcal meningitis treatment in South Africa. In a survey of 25 sentinel hospitals in South Africa, the use of amphotericin B for cryptococcal meningitis induction treatment increased substantially, from 34% in 2005 to 83% in 2010. 38 Access to amphotericin B might be further restricted by uncoordinated funding, procurement, and distribution of the drug. In low-income and middle-income countries, amphotericin B is funded, procured, and distributed by diff erent organisations, both governmental (President's Emergency Plan for AIDS Relief, the Global Fund, UNITAID) and non-governmental (International Drug Purchase Facility, Doctors Perceived unmanageable toxic eff ects as a result of insuffi cient local education and inadequate facilities for safe administration and monitoring are an important disincentive to clinician uptake of amphotericin B for adults with cryptococcal meningitis, even when use is recommended by guidelines. This situation causes a fall in demand, which might contribute to intermittent failures of supply chains (in both high-income and lowincome countries 35 ). At least three diff erent lipid-based formulations are marketed (table 4). The most widely used liposomal intravenous formulation is AmBisome (Gilead Sciences, CA, USA), the patent of which has recently expired in several countries. Dosed at 3 mg/kg per day, it is substantially less nephrotoxic than amphotericin B, but is prohibitively expensive for low-income and middleincome countries (2011 British National Formulary list price per 50 mg vial: $150 in the UK; CIMS list price $225 in India). A substantial reduction in price to $18 per 50 mg vial was negotiated by WHO for their visceral leishmaniasis programme. 39 An equivalent price was off ered by Gilead Sciences to the South African Government for treatment of patients with cryptococcal meningitis (N Geff en, Treatment Action Campaign, personal communication), but was not accepted. Gilead recently donated 445 000 vials of AmBisome for use over 5 years for the WHO visceral leishmaniasis programme. 40 Fungisome (Lifecare Innovations Ltd, India) a liposomal formulation of amphotericin B developed and trialled in India, 41 has a maximum retail price of $122 per 50 mg vial for the local market (table 4) . Therefore, cost remains an important barrier to a switch from con ventional to less toxic liposomal formulations of amphotericin B in lowincome and middle-income countries. Cheap in-house pre parations of amphotericin B lipid emulsions, with rates of nephrotoxicity com parable to liposomal formulations, warrant further effi cacy studies in low-income and middle-income countries. 42 So far, only intravenous formulations of amphotericin B have been licensed. New oral formulations of amphotericin B are in early stages of development as part of the drive to improve access to treatment for visceral leishmaniasis, 43, 44 
Personal View
British Columbia who devised the initial formulation, [45] [46] [47] [48] [49] iCoTherapeutics are committed to ensuring access to these formulations for treatment of visceral leishmaniasis in some low-income and middle-income countries, while allowing the company to pursue more lucrative highincome markets for treatment of fungal infections.
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Flucytosine
Flucytosine was created in 1957 as a potential antitumour agent, and fi rst used to treat human candidiasis and cryptococcosis in 1968. 51, 52 Flucytosine exerts its antifungal activity through rapid conversion into 5-fl uorouracil, 51, 53 and is available in intravenous and oral formulations, marketed as Ancotil 2·5 g/250 ml solution for infusion and Ancobon (Meda Pharmaceuticals, France) 500 mg capsules. Flucytosine is always used in combination with other antifungals because resistance emerges rapidly to monotherapy. Side-eff ects are mediated by 5-fl uorouracil, and include gastrointestinal and bone marrow toxic eff ects. [53] [54] [55] [56] Studies in low-income and middle-income countries have shown that oral fl ucytosine can be used safely and eff ectively without monitoring drug levels in settings in which complete blood count and renal function are monitored and dosing intervals are extended if renal impairment occurs. 23, 26, 28, 30 Flucytosine can be given nasogastrically in unconscious patients. 25 The use of fl ucytosine was originally restricted because of the drug's toxic eff ects at high doses (150 mg/kg per day); however, since the 1980s, clinical trials of cryptococcal meningitis with progressively shorter courses of fl ucytosine at lower doses (100 mg/kg per day) have shown that fl ucytosine can be used safely and eff ectively in combination with amphotericin B (0·7-1 mg/kg per day). 25, 26, 29 A trial in Vietnam showed an association between decreased mortality rates and treatment with fl ucytosine and amphotericin B compared with treatment with amphotericin B alone. 29 Therefore, 2 weeks of amphotericin B plus fl ucytosine remains the gold standard for induction treatment of cryptococcal meningitis. In lowincome and middle-income countries, where amphotericin B treatment is not available or feasible, fl ucytosine can be safely and eff ectively paired with high-dose fl uconazole (1200 mg/day), [57] [58] [59] [60] as recommended by IDSA and WHO guidelines. 16, 17 Despite these guideline recommendations, fl ucytosine is not yet available in most of Asia and Africa (table 3). The main barriers to access to fl ucytosine include absence of drug registration and generic drug manufacturing in low-income and middle-income countries. Flucytosine is not registered in any African country. 35, 37 Flucytosine was previously marketed by Roche in South Africa, but registration of the drug lapsed in 1996. The local National Health Service trust tender price for oral fl ucytosine is 85p ($1·33) per 500 mg tablet for Ancobon (L Whitney, St George's Hospital Pharmacy, personal com muni cation), or $182 for a 50 kg adult with cryptococcal meningitis receiving 14 days of induction treatment. Conversely, generic oral fl ucytosine, manufactured by Sigmapharm, and approved by the FDA in 2011, retails in the USA at $34 per 500 mg fl ucytosine tablet (A Sheppard, IMS Health, personal communication) or $4760 per 14-day course. Although fl ucytosine is a nucleotide analogue of simple chemical structure that has been off -patent for many years, there seems to be market failure because of insuffi cient demand and supply. A sustained eff ort is needed to make this key component of cryptococcal meningitis treatment more widely available in low-income and middle-income countries.
Fluconazole
Fluconazole has excellent bioavailability and cerebrospinal fl uid (CSF) penetration and few adverse eff ects. 61, 62 The drug is available in intravenous formulation and is commonly given orally to treat cryptococcal meningitis. Clinical and mycological outcomes in trials of low-dose fl uconazole monotherapy (200-400 mg/day) as induction treatment have been disappointing, with high mortality and prolonged time to CSF sterilisation. 15, 63, 64 This slow fungal clearance can predispose to development of secondary drug resistance and cryptococcal immune reconstitution syndrome. [65] [66] [67] Phase 2 studies 30,68 with highdose fl uconazole in com bination with amphotericin B yielded good mycological and clinical outcomes and, in a larger trial, no diff erence in 2 week and 10 week mortality was evident between amphotericin B plus fl uconazole 800 mg/day and amphotericin B plus fl ucytosine. 29 Therefore, WHO and IDSA guidelines recommend the use of amphotericin B with high-dose fl uconazole as second-line induction antifungal regimens. 16, 17 Higher doses of fl uconazole (800-1200 mg/day) as induction treatment are well tolerated and have faster rates of fungal clearance than a dose of 400 mg daily. 69 Clearance rates are further improved when fl uconazole is combined with fl ucytosine. 57, 58 WHO guidelines include high-dose fl uconazole monotherapy as an induction treatment option (table 1), but only when amphotericin B and fl ucytosine are unavailable. 16 Fluconazole is also a cornerstone of consolidation and maintenance treatment of cryptococcal meningitis [16] [17] [18] with published guidelines recommending step-down to fl uconazole after the initial 2 week induction to prevent recurrence of disease. [16] [17] [18] Since 2012, fl uconazole has also been used to treat early cryptococcal disease detected through cryptococcal antigen screening. 70 Pre-emptive treatment of patients with a CD4 count less than or equal to 100 cells per μL and asymptomatic cryptococcal antigenaemia with fl uconazole is being piloted in South Africa as a public health strategy to reduce death and morbidity caused by cryptococcal meningitis. 67, 71 Fluconazole is off patent, generally widely available and cheap, and numerous generic versions have FDA approval (table 4, price range with WHO Global Price Reporting Mechanism: $0·08-$1·36 per day when dosed at 800 mg 36 ). Although cost has greatly restricted access to fl uconazole in the past, 72 availability has gradually improved through increased production by generic manufacturers. Since 2000, Pfi zer's (NY, USA) Difl ucan Partnership programme has provided free Difl ucan to 63 low-income and middle-income countries for the treatment of patients with cryptococcal meningitis and oesopha geal candidiasis (not for the pre-emptive treatment of cryptococcal antigenaemia) and is set to continue indefi nitely (Difl ucan Partnership programme, Pfi zer, personal communication). However, imple mentation of the programme varies: at teaching hospital pharmacies at investigators' collaborating trial sites in South Africa (Cape Town, Pietermaritzburg, and Durban) and Uganda (Mbarara and Kampala), donated Difl ucan is readily available, whereas in Malawi (Blantyre and Lilongwe), Zambia (Lusaka), Cameroon (Douala and Yaoundé), and Tan zania (Arusha), purchased generic fl uconazole rather than donated Difl ucan is in stock, attributable to the challenges of sustaining timely and streamlined ordering through the donation programme. Although free fl uconazole has been crucial for the treatment of cryptococcal meningitis in Africa, increased availability of fl uconazole by comparison with amphotericin B might have led to clinicians favouring fl uconazole over amphotericin B-based induction treatment.
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Recommendations for improvement of access to antifungals
We propose ten measures to improve access to cryptococcal meningitis treatment (panel). Improved estimates of disease burden, building upon studies by the CDC, 13 either via national cryptococcal surveillance systems (eg, South African National Institute for Communicable Diseases) 75 or through localised epidemiological studies, would help with drug forecasting, streamline ordering, and maximise the use of donations. Such data would allow estimates of market size for manufacturers to be made and allow competitive price negotiation.
The 2011 WHO rapid advice guidelines 16, 76 provide recommendations on antifungal regimens tailored to clinical settings (table 1) , and off ers guidance on how to minimise toxic eff ects and monitor amphotericin B, [16] [17] [18] so that increased access does not produce more harm than good. These recommendations need to be translated into country-specifi c or region-specifi c treatment guidelines, 18 and implemented alongside capacity building measures to improve facilities for rapid diagnosis, monitoring of toxic eff ects, and fast-track referral into antiretroviral therapy programmes.
In the WHO Model List of Essential Medicines,the core (the most effi cacious, safe and cost-eff ective medicines for priority conditions for use in a basic health-care 5-11 Antifungal drugs should be registered in lowincome and middle-income countries, and a requirement to show bio equivalence, quality standards (ie, good manufacturing practice), and eff ectiveness of new generic formulations should be included. In many low-income and middle-income countries, medicines regulatory authorities are hampered by insuffi cient resources and human capacity. Successful registration of antifungal drugs might need support from experienced authorities such as the Medicines Control Council of South Africa, the FDA, or European Medicines Agency, 77 or even the introduction of a pan-African reciprocal drug-approval process. In South Africa, eff orts are underway for fasttrack registration of fl ucytosine with the Medicines Control Council (C Chuma, Lighthouse Healthcare, personal communication).
Drug companies should include antifungals in corporate responsibility policies on HIV, and consider preferential pricing for low-income and middle-income countries. Increased competition through generation of generics is needed. Generic pharmaceutical manufacturers should be given incentives and manufacturing support to produce generic versions of fl ucytosine for the low-income and middle-income country markets. South Africa is exploring the manufacture of cheaper generic fl ucytosine at facilities contracted by GSK and Pfi zer in Bangladesh; a lengthy process that needs a full Medicines Control Council inspection (C Chuma, Lighthouse Healthcare, personal communication). Pooled procurement of anti fungals would increase availability and secure com petitive prices, through eff ective coordination of regional governments, global health organisations and funders, and pharma ceutical companies and distributors. 78 Drug funding and distribution could be integrated with existing antiretroviral therapy programmes to provide antifungals alongside antiretrovirals, antituberculous drugs, and co-trimoxazole.
The optimisation of antifungal regimens in mortalityendpoint trials in low-income and middle-income countries is a driver for policy change. A multicentre African phase 3 trial (ISRCTN 45035509) is comparing standard with short-course amphotericin B-based regimens and a purely oral combination (ie, fl uconazole plus fl ucytosine). Additionally, socially responsible licensing of intellectual property 79 should apply to new antifungals or formulations made through research funded by the public or by foundations. To our knowledge, only one new long-acting azole-like compound is in development in a joint project between Viamet pharmaceuticals and the NIH Therapeutics for Rare and Neglected Diseases programme. 80 The scarcity of drug development for cryptococcal meningitis is in stark contrast to the range of new drugs emerging from product-development partnerships for the treatment of malaria and tuberculosis, 81 diseases that are associated with a comparable mortality burden to cryptococcal meningitis in subSaharan Africa. 13 The research and advisory group Policy Cures lists three criteria essential to classify a disease as neglected: 81 the disease must predominantly aff ect people in lowincome countries; needs new, improved, or additional products; and suff ers from market failure because of an insuffi cient commercial market, resulting in insuffi cient research and development by industry. Cryptococcal meningitis fulfi ls all of these criteria. Offi cial classifi cation of cryptococcal meningitis as a neglected disease would help attract funding for drug development.
Conclusions
Although continued global scale-up of antiretroviral therapy and initiation before the CD4 count falls below 350 cells per μL remains the most important long-term strategy to reduce the incidence of cryptococcal meningitis, the infection will remain a major cause of HIV-related morbidity and mortality, particularly in sub-Saharan Africa in the foreseeable future. Treatment for cryptococcal meningitis relies on three old, off -patent antifungal drugs, which each pose specifi c access challenges for low-income and middle-income countries: amphotericin B through cost, toxic eff ects, and insuffi ciently coordinated distribution; fl ucytosine through cost and insuffi cient registration; and fl uconazole through challenges to maintenance of local stocks, be it through sustainability of Personal View donations or insuffi cient generic supplies. If patients with crypto coccal meningitis survive the acute disease and become established on antiretroviral therapy, long-term prog nosis is excellent. 15 It is unacceptable that up to one half of patients with cryptococcal meningitis in low-income and middle-income countries do not survive to 10 weeks, and do not benefi t from expansion of antiretroviral therapy programmes, partly because even the basic range of antifungal drugs is not available to them.
Access to the most eff ective antifungal drugs for treatment of cryptococcal meningitis in developing countries needs to be urgently improved as part of the global response to the HIV pandemic. A concerted move away from the widely-practised fl uconazole monotherapy, towards more eff ective combination induction treatment regimens including amphotericin B or fl ucytosine or both, is needed. A coordinated international eff ort should involve relevant public and private organisations and we must learn from models with proven success in the implementation of access to medicines for other important global infectious diseases. Facilitated by WHO, a meeting of key stakeholders took place in March 2013 and has given rise to a concerted advocacy eff ort to improve access to essential antifungals for cryptococcal meningitis.
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